Annovis Bio, Inc.

Overview

Annovis Bio, Inc. is a clinical-stage American biotechnology company headquartered in Berwyn, Pennsylvania, focused on developing novel treatments for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative disorders. The company's lead compound, bunodimod (formerly Annovis-101), targets multiple neurotoxic proteins. [@annovis]

Company Overview

| Attribute | Details | [@bunodimod]
|-----------|---------| [@bunodimoda]
| Ticker | NYSE: ANVS | [@sigma2020]
| Headquarters | Berwyn, Pennsylvania, USA |
| Founded | 2009 (as ALLERVIS, renamed 2019) |
| CEO | Maria Maccecchini |
| Employees | ~20 |
| Market Cap | ~$50 million (2024) |

Pipeline Overview

Lead Compound: Bunodimod (ANAVEX 2-73)

| Drug | Mechanism | Phase | Indication |
|------|-----------|-------|------------|
| Bunodimod | Sigma-1 agonist / [mTOR](/mechanisms/mtor-signaling-pathway) inhibitor | Phase 2/3 | AD, PD |

Bunodimod (ANAVEX 2-73)

• Mechanism: Sigma-1 receptor agonist and mTOR inhibitor
• Targets: Sigma-1 receptor, mTOR pathway
• Phase: Phase 2/3 (NCT05514170 for AD, NCT04577352 for PD)
• Status: Recruiting
• Clinical Trials:
• [AD Study](https://clinicaltrials.gov/show/NCT05514170)
• [PD Study](https://clinicaltrials.gov/show/NCT04577352)

Mechanism of Action

Overview

Annovis Bio, Inc. is a clinical-stage American biotechnology company headquartered in Berwyn, Pennsylvania, focused on developing novel treatments for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative disorders. The company's lead compound, bunodimod (formerly Annovis-101), targets multiple neurotoxic proteins. [@annovis]

Company Overview

| Attribute | Details | [@bunodimod]
|-----------|---------| [@bunodimoda]
| Ticker | NYSE: ANVS | [@sigma2020]
| Headquarters | Berwyn, Pennsylvania, USA |
| Founded | 2009 (as ALLERVIS, renamed 2019) |
| CEO | Maria Maccecchini |
| Employees | ~20 |
| Market Cap | ~$50 million (2024) |

Pipeline Overview

Lead Compound: Bunodimod (ANAVEX 2-73)

| Drug | Mechanism | Phase | Indication |
|------|-----------|-------|------------|
| Bunodimod | Sigma-1 agonist / [mTOR](/mechanisms/mtor-signaling-pathway) inhibitor | Phase 2/3 | AD, PD |

Bunodimod (ANAVEX 2-73)

• Mechanism: Sigma-1 receptor agonist and mTOR inhibitor
• Targets: Sigma-1 receptor, mTOR pathway
• Phase: Phase 2/3 (NCT05514170 for AD, NCT04577352 for PD)
• Status: Recruiting
• Clinical Trials:
• [AD Study](https://clinicaltrials.gov/show/NCT05514170)
• [PD Study](https://clinicaltrials.gov/show/NCT04577352)

Mechanism of Action

Bunodimod is a small molecule with dual mechanism:

The company claims this "single molecule, multiple targets" approach addresses multiple pathologies simultaneously:

• Reduces [amyloid-beta](/proteins/amyloid-beta) production
• Reduces [tau](/proteins/tau) phosphorylation
• Reduces [alpha-synuclein](/proteins/alpha-synuclein)
• Reduces [TDP-43](/mechanisms/tdp-43-proteinopathy)

Alzheimer's Disease Program

Phase 2/3 Clinical Trial

• Study: Placebo-controlled, randomized
• Population: Early AD patients
• Primary Endpoint: Change in cognition (ADAS-Cog)
• Status: Recruiting (as of 2024)

Preclinical Data

• Reduced amyloid-beta in animal models
• Improved cognition in AD mouse models

Parkinson's Disease Program

Phase 2/3 Clinical Trial

• Study: Placebo-controlled, randomized
• Population: Early PD patients
• Primary Endpoint: Change in motor symptoms (MDS-UPDRS)
• Status: Recruiting (as of 2024)

Preclinical Data

• Reduced alpha-synuclein aggregation
• Improved motor function in PD models

Other Pipeline Programs

| Drug | Mechanism | Phase |
|------|-----------|-------|
| ANAVEX 2-73 | Sigma-1 agonist | Phase 2/3 |
| ANAVEX 1-41 | Sigma-1 agonist | Phase 1 |
| ANAVEX 3-71 | Sigma-1 agonist | Preclinical |

ANAVEX 1-41

• Mechanism: Sigma-1 receptor agonist
• Phase: Phase 1 (completed)
• Indication: Depression/anxiety

ANAVEX 3-71

• Mechanism: Sigma-1 and Sigma-2 agonist
• Phase: Preclinical
• Rationale: Dual sigma receptor modulation

Scientific Rationale

The company's approach is based on the "multiple hit" hypothesis of neurodegeneration:

• Multiple proteins become dysregulated in neurodegenerative diseases
• Targeting a single protein may not be sufficient
• Sigma-1 receptor modulation affects multiple pathways

Financial Highlights

| Year | Revenue | Cash | Key Programs |
|------|---------|------|--------------|
| 2023 | $0 | $30M | Bunodimod |
| 2022 | $0 | $40M | Bunodimod |
| 2021 | $0 | $50M | Bunodimod |

Key Leadership

• Maria Maccecchini - CEO and Founder
• Cameron - CMO
• Pat - CSO

Related Companies

• [Biogen](/companies/biogen) - Major player in AD/PD
• [Eli Lilly](/companies/eli-lilly) - AD pipeline competitor
• [Roche](/companies/roche) - Neuroscience pipeline
• [Eisai](/companies/eisai) - AD partnership with Biogen
• [Denali Therapeutics](/companies/denali) - Neurodegeneration focus

External Links

• [ClinicalTrials.gov Search](https://clinicaltrials.gov/search?spons=Annovis+Bio)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Annovis Bio, Inc. discovered through SciDEX knowledge graph analysis: